73 results
Should we perform revascularisation in patients with depressed left ventricle ejection fraction?
17 May 2023 – From EuroPCR 2023
Divaka Perera, main author of the REVIVED study, discusses the results of this trial with Flavio Ribichini.
REVIVE was a trial of severe ischaemic cardiomyopathy in which the primary outcome was death or heart failure hospitalization.The headline result was that there was absolutely no difference with PCI,...
Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock
03 Jul 2023
This is the largest real world observational data that confirms the safety and efficacy of TAVR for the treatment of patients with severe aortic stenosis presenting with cardiogenic shock.
Reviewer
Reviewer
When it’s (really) tight
23 Jun 2023
A 71-year-old woman was referred for coronary angiography. She underwent SAVR for AS related to bicuspidia 6 months before, and subsequently suffered from angina and increasing dyspnea 4 months after the intervention...
Author
Author
Author
Embolic protection, TAVI, heart failure and artificial intelligence: what's new in 2023
19 May 2023 – From EuroPCR 2023
This session covers various topics related to transcatheter aortic valve replacement, including the Protect Head-to-Head study on full-body embolic protection during TAVR, the FLOWer device for complete embolic protection, the use of a pulsing aspiration pump for percutaneous thrombectomy, and many more innovation updates from 2023.
How have REVIVED (percutaneous revascularization for ischemic left ventricular dysfunction) results changed my practice?
17 May 2023 – From EuroPCR 2023
Mirvat Alasnag and Ajay Kirtane reflect on the REVIVED (percutaneous revascularization for ischemic left ventricular dysfunction) randomised trial 9 months after its release. They discuss how the unexpected results had an effect on their practice, and how results compare to those of the STICH trial.
Outcomes of medical therapy plus PCI for multivessel or left main CAD ineligible for surgery
09 Mar 2023
The OPTIMUM study evaluates the outcomes in patients with complex CAD, including significant LM disease, its equivalent, or MVD CAD, undergoing percutaneous revascularization in addition to guideline directed medical therapy (GDMT) versus GDMT alone.
Reviewer
Reviewer
AIMI-HF trial - Ischemia and viability imaging in heart failure: The alternative imaging modalities in ischemic heart failure trial
05 Mar 2023
Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.
Author
Effect of myocardial viability, percutaneous coronary intervention and functional recovery on clinical outcomes in the REVIVED-BCIS2 randomized trial
13 Mar 2023
Dejan Milasinovic provides his take on this clinical trial which was presented by Divaka Perera (London, United Kingdom), at the American College of Cardiology (ACC/WCC) 2023 Scientific Session.
Author
Clinical and economic burden of reduced PCI access during UK COVID-19 lockdown – A We CARE analysis
18 May 2022 – From EuroPCR 2022
Across Europe, during the COVID pandemic, there was a big reduction in patients presenting for primary PCI. Interviewed by Nicola Ryan, Mamas Mamas summarises the key points from the We CARE study which analysed the effect at the population level in terms of heart failure diagnosis, cost...
PCR Innovators Day - Follow-up and technology updates
19 May 2022 – From EuroPCR 2022
In this EuroPCR 2022 session, find out more about how mastering heart failure treatment by empowering physicians and patients, discover a novel approach for fluid removal, an adjustable interatrial shunt system, and much more!
